NO20055668L - Beta-amyloidinhibitorer og anvendelse derav - Google Patents

Beta-amyloidinhibitorer og anvendelse derav

Info

Publication number
NO20055668L
NO20055668L NO20055668A NO20055668A NO20055668L NO 20055668 L NO20055668 L NO 20055668L NO 20055668 A NO20055668 A NO 20055668A NO 20055668 A NO20055668 A NO 20055668A NO 20055668 L NO20055668 L NO 20055668L
Authority
NO
Norway
Prior art keywords
beta
amyloid
amyloid inhibitors
dernentia
pugilistica
Prior art date
Application number
NO20055668A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055668D0 (no
Inventor
Luca Barbero
Silvio Traversa
Pierandrea Esposito
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20055668D0 publication Critical patent/NO20055668D0/no
Publication of NO20055668L publication Critical patent/NO20055668L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Navigation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20055668A 2003-04-30 2005-11-30 Beta-amyloidinhibitorer og anvendelse derav NO20055668L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03101202 2003-04-30
PCT/EP2004/004807 WO2004096845A2 (en) 2003-04-30 2004-04-29 Beta-amyloid inhibitors and use thereof

Publications (2)

Publication Number Publication Date
NO20055668D0 NO20055668D0 (no) 2005-11-30
NO20055668L true NO20055668L (no) 2005-11-30

Family

ID=33395961

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055668A NO20055668L (no) 2003-04-30 2005-11-30 Beta-amyloidinhibitorer og anvendelse derav

Country Status (7)

Country Link
US (1) US20070293422A1 (de)
EP (1) EP1618129A2 (de)
JP (1) JP2007523848A (de)
AU (1) AU2004234076A1 (de)
CA (1) CA2522460A1 (de)
NO (1) NO20055668L (de)
WO (1) WO2004096845A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE112007001030T5 (de) * 2006-04-28 2009-02-26 Kagoshima University Amyloid-ß-Fibrillogenese-inhibierendes Peptid
SG10201604103SA (en) * 2011-05-31 2016-07-28 Hutchison Biofilm Medical Solutions Ltd Dispersion and detachment of cell aggregates
KR102475326B1 (ko) * 2022-01-27 2022-12-07 한국기초과학지원연구원 신규한 펩타이드 유사체 및 이를 포함하는 알츠하이머 병 예방 조성물
CN114594272B (zh) * 2022-05-07 2022-08-23 北京第一生物化学药业有限公司 用于检测β-淀粉样蛋白的产品和方法
CN114578066B (zh) * 2022-05-07 2022-08-19 北京第一生物化学药业有限公司 检测β-淀粉样蛋白的产品和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854204A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
US6399584B1 (en) * 1998-03-18 2002-06-04 Institute Curie Pharmaceutical composition containing ezrin mutated on tyrosine 353
AU766489B2 (en) * 1998-11-13 2003-10-16 Cyclacel Limited Transport vectors
US6303576B1 (en) * 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression
GB9917724D0 (en) * 1999-07-28 1999-09-29 Medical Res Council Peptides
AU2002250034A1 (en) * 2001-02-08 2002-08-19 Sequitur, Inc. Methods of light activated release 0f ligands from endosomes
FR2829940A1 (fr) * 2001-09-27 2003-03-28 Synt Em Compositions pour la vectorisation d'anticorps a travers la barriere hematoencephalique et leur utilisation pour le diagnostic ou le traitement des maladies du systeme nerveux central

Also Published As

Publication number Publication date
CA2522460A1 (en) 2004-11-11
AU2004234076A1 (en) 2004-11-11
JP2007523848A (ja) 2007-08-23
WO2004096845A3 (en) 2005-01-06
NO20055668D0 (no) 2005-11-30
EP1618129A2 (de) 2006-01-25
US20070293422A1 (en) 2007-12-20
WO2004096845A2 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
NO20070081L (no) Sulfamat og sulfamidderivater for behandling av epilepsi og relaterte sykdommer
NO20063200L (no) Preparat for forbedring av hud-, har og pelshelse inneholdende flavanoner
NO20045137L (no) Diketohydrazinderivatforbindelser og legemidler inneholdende forbindelser som aktiv ingrediens
NO20052223L (no) Tiazolforbindelser for behandling av neurodegenerative forstyrrelser
FI961438A7 (fi) beta-amyloidiproteiinituotannon estäjiä
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
NO20053263L (no) Hydroksyetylaminderivater for behandling av Alzheimers sykdom.
NO20040511L (no) Aminoisoxazolderivater som kinaseinhibitorer
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
NO20053077L (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
MXPA06000930A (es) Regulacion del tejido queratinoso mamifero utilizando composiciones de n-acilaminoacido.
CA2188817A1 (en) Angiogenesis inhibitor
DE69233108D1 (de) Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
NO975192L (no) Bicykliske aromatiske forbindelser
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
NO20076405L (no) Anvendelse av 24-nor-UDCA
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
NO20055668L (no) Beta-amyloidinhibitorer og anvendelse derav
NO20063137L (no) Tricykliske indolhydroksyetylaminderivater og deres anvendelse i behandlingen av Alzheimers sykdom
NO20070665L (no) Derivater av 1-fenylalkankarboksylsyrer for behandlingen av neurodegenerative sykdommer
ZA200701798B (en) Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalioproteinases inhibitors
DE602004023721D1 (de) Zusammensetzungen und methoden für die behandlung von herzerkrankungen
CY1114209T1 (el) Φαρμακευτικες και καλλυντικες συνθεσεις που περιλαμβανουν plgf-1

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application